A Role for BRCA1 in Uterine Leiomyosarcoma
Authors:
- George ScangasGSGeorge Scangas
- Mai NittaMNMai Nitta
- Lei HeLHLei He
- Xuan XuXXXuan Xu
- Yevgeniya J.M. IoffeYIYevgeniya J.M. Ioffe
- Paul-Joseph AspuriaPAPaul-Joseph Aspuria
- Cyrus Y. HedvatCHCyrus Y. Hedvat
- Matthew L. AndersonMAMatthew L. Anderson
- Esther OlivaEOEsther Oliva
- Beth Y. KarlanBKBeth Y. Karlan
- Gayatry MohapatraGMGayatry Mohapatra
- 28 October 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (21) , 8231-8235
Abstract
Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate. Currently, there is no effective treatment for ULMS. Infrequent occurrences of human ULMS hamper the understanding of the initiation and progression of the disease, thereby limiting the ability to develop efficient therapies. To elucidate the roles of the p53 and BRCA1 tumor suppressor genes in gynecologic malignancies, we generated mice in which p53 and/or BRCA1 can be conditionally deleted using anti-Müllerian hormone type II receptor (Amhr2)–driven Cre recombinase. We showed that conditional deletion of p53 in mice results in the development of uterine tumors that resemble human ULMS and that concurrent deletion of p53 and BRCA1 significantly accelerates the progression of these tumors. This finding led to our hypothesis that BRCA1 may play a role in human ULMS development. Consistent with this hypothesis, we showed that the BRCA1 protein is absent in 29% of human ULMS and that BRCA1 promoter methylation is the likely mechanism of BRCA1 downregulation. These data indicate that the loss of BRCA1 function may be an important step in the progression of ULMS. Our findings provide a rationale for investigating therapies that target BRCA1 deficiency in ULMS. [Cancer Res 2009;69(21):8231–5]Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General HospitalGynecologic Oncology, 2004
- A Mouse Model of Uterine LeiomyosarcomaThe American Journal of Pathology, 2004
- Requirement of Bmpr1a for Müllerian duct regression during male sexual developmentNature Genetics, 2002
- Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancerNature Genetics, 2001
- Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesisNature Genetics, 2001
- Transcriptional regulation of the rat Müllerian inhibiting substance type II receptor in rodent Leydig cellsProceedings of the National Academy of Sciences, 1999
- Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formationNature Genetics, 1999
- Amplification of themdm-2 gene andp53 abnormalities in uterine sarcomasInternational Journal of Cancer, 1997
- Mouse mammary tumor virus/v-Ha- ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4Proceedings of the National Academy of Sciences, 1997
- p53 Alterations in Uterine Leiomyosarcomas versus LeiomyomasGynecologic Oncology, 1994